Efficacy of a new antihypertensive agent (indenolol) assessed by ambulatory blood pressure monitoring.

Efficacy of a new antihypertensive agent (indenolol) assessed by ambulatory blood pressure monitoring. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Efficacy of a new antihypertensive agent (indenolol) assessed by ambulatory blood pressure monitoring. Abstract Text:

B Trimarco,G Groothold,D Bonaduce,A Cuocolo,B Ricciardelli,V Canonico,R Breglio,M Condorelli,

The effects of two-week treatment periods with indenolol (I) and metoprolol (M) were examined by 24-hour mean blood pressure (BP) monitoring in control conditions and during exercise stress test in 7 patients with essential hypertension, using the Oxford method. Both drugs induced a significant reduction in mean BP and heart rate (HR) as compared to pretreatment values (mean BP: from 117 +/- 3 mmHg to 106 +/- 4 after I, p less than 0.05 and to 102 +/- 3 after M, p less than 0.01; HR: from 78 +/- 2 bpm to 66 +/- 2 after I, p less than 0.01 and to 67 +/- 2 after M, p less than 0.01). I and M induced a significant reduction in systolic and diastolic BP throughout the day and most of the night. During bicycle ergometer the basal and peak values of systolic and diastolic BP were significantly lower after both treatments as compared to the pretreatment values (both p less than 0.01). Our data suggest that I once a day possesses a substantial and consistent antihypertensive action, effective over most of the 24 hours.

Efficacy of a new antihypertensive agent (indenolol) assessed by ambulatory blood pressure monitoring. Publishing Authors By Initials

B Trimarco,G Groothold,D Bonaduce,A Cuocolo,B Ricciardelli,V Canonico,R Breglio,M Condorelli,

For similar organic chemicals: alcohols: amino alcohols: propanolamines research abstracts see: organic chemicals: alcohols: amino alcohols: propanolamines research

PUBMED ID PMID:

MEDLINE DATE:

Efficacy of a new antihypertensive agent (indenolol) assessed by ambulatory blood pressure monitoring. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Clinical and experimental hypertension. Part A, Th

VOLUME: 7

Page Numbers: 395-9

Journal Abbreviation:

ISSN: 0730-0077

DAY: 12

MONTH: 02

YEAR: 1985

Efficacy of a new antihypertensive agent (indenolol) assessed by ambulatory blood pressure monitoring. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8207790

Efficacy of a new antihypertensive agent (indenolol) assessed by ambulatory blood pressure monitoring. Keywords Mesh Terms:

KEYWORDS: Propanolamines

MESH TERMS: therapeutic use

Chemical & Substance for Abstract: Efficacy of a new antihypertensive agent (indenolol) assessed by ambulatory blood pressure monitoring. Information

Substance Name: indenolol

Registry Number: 60607-68-3

Grant and Affiliation Information for Efficacy of a new antihypertensive agent (indenolol) assessed by ambulatory blood pressure monitoring.

AFFILIATION:

Country: UNITED STATES

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Exp Hypertens A

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Efficacy of a new antihypertensive agent indenolol assessed by ambulatory blood pressure monitoring Related Publications

• A lentiviral vector with a short troponin-I promoter for tracking cardiomyocyte differentiation of human embryonic stem cells.
• Cardiac-specific overexpression of E40K active Akt prevents pressure overload-induced heart failure in mice by increasing angiogenesis and reducing apoptosis.
• Contrast agents and renal cell apoptosis.
• Deciphering the beta-adrenergic response in human embryonic stem cell-derived-cardiac myocytes: closer to clinical use?
• Deciphering the beta-adrenergic response in human embryonic stem cell-derived-cardiac myocytes: closer to clinical use?
• Efficacy of a new antihypertensive agent (indenolol) assessed by ambulatory blood pressure monitoring.
• Emerging Role of MicroRNAs in Cardiovascular Biology.
• Identification and functional expression of HCx31.9, a novel gap junction gene.
• MicroRNA and cardiac pathologies.
• MicroRNA-133 controls cardiac hypertrophy.
• MicroRNAs Control Gene Expression: Importance for Cardiac Development and Pathophysiology.
• NAD depletion by FK866 induces autophagy.
• Not Available
• On the road to the definition of the cardiac miRNome in human disease states.
• Physiological myocardial hypertrophy: how and why?
• State-of-the-Art Prevention of Heart Failure: Maladaptive versus Adaptive Hypertrophy.
• [Not Available.]
• [Not Available.]
• [Primary neuraxitis endemic in Italy of probable viral nature and its relation to viral neuraxitis of ascertained and nosographically definite etiology.]